Attralus Receives FDA and EMA Orphan Designation for AT-01

SAN FRANCISCO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to...

Related Keywords

United States ,San Francisco ,California ,Gregory Bell ,Isabelle Lousada ,Krishna Gorti ,University Of Tennessee Medical Center ,European Commission ,Drug Administration ,Attralus Inc ,University Of Tennessee Research Foundation ,Attralus Communications ,Committee For Orphan Medicinal Products ,European Medicines Agency ,Amyloidosis Research Consortium ,Orphan Medicinal Products ,Chief Medical Officer ,Tennessee Medical Center ,Amyloidosis Research ,Drug Designation ,Orphan Drug Designation ,Tennessee Research ,Amyloid Light Chain ,Plight Chain ,Transthyretin Amyloidosis ,Attralus ,Nc ,